



# The optimal duration of dual antiplatelet therapy in patients receiving percutaneous coronary intervention with drug-eluting stents

Olusegun Sheyin<sup>1</sup>, Xavier Perez<sup>1</sup>, Bredy-Pierre-Louis<sup>2</sup>, Damian Kurian<sup>2</sup>

<sup>1</sup>Department of Medicine, Harlem Hospital Center, Columbia University  
College of Physicians and Surgeons, New York, United States

<sup>2</sup>Division of Cardiology, Department of Medicine, Harlem Hospital Center,  
Columbia University College of Physicians and Surgeons, New York, United States

## Abstract

**Background:** *The optimal duration of dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) implantation remains a subject of an ongoing debate.*

**Methods:** *MEDLINE, EMBASE, Scopus and CENTRAL databases were searched for eligible randomized controlled trials (RCTs) that compared short-term ( $\leq 6$  months) DAPT with long-term ( $\geq 12$  months) DAPT following DES implantation. The primary endpoint was a composite of all-cause mortality, myocardial infarction (MI), target vessel revascularization (TVR), stroke, or major bleeding. The secondary outcome were the individual components of the primary outcome, cardiovascular death, stent thrombosis and any bleeding episode.*

**Results:** *A total of 15,378 patients from 7 RCTs were studied. There were no statistically significant differences between the short-term and long-term DAPT groups with respect to the occurrence of the primary outcome (risk ratio [RR] 1.017; 0.872–1.186;  $I^2 = 0\%$ ), all cause death (RR 0.896; 0.708–1.134), cardiovascular death (RR 0.924; 0.668–1.279), MI (RR 1.139; 0.887–1.461), TVR (RR 1.174; 0.916–1.505), stent thrombosis (RR 1.264; 0.786–2.032), and stroke (RR 0.876; 0.685–1.611). However, there was a statistically significant lower risk of major bleeding in the short-term DAPT group (RR 0.57; 0.36–0.90;  $p = 0.02$ ). There were no statistically significant differences in the sub-group analysis of patients with diabetes and patients presenting with acute coronary syndrome, RR 1.029; 0.745–1.421 and RR 1.062; 0.785–1.438, respectively.*

**Conclusions:** *There was no difference in efficacy outcomes between short-term and long-term DAPT following DES, even among high-risk patients. However, longer duration of DAPT was found to be associated with increased risk of major bleeding. (Cardiol J 2016; 23, 3: 307–316)*

**Keywords:** dual antiplatelet therapy, drug-eluting stent, bleeding, stent thrombosis

## Introduction

Drug-eluting stents (DES) reduce the incidence of target lesion restenosis when compared

with bare metal stents, yet they are prone to higher rates of stent thrombosis [1]. Dual antiplatelet therapy (DAPT), defined as the use of both aspirin and a P2Y<sub>12</sub> receptor inhibitor, such as clopidogrel,

**Address for correspondence:** Olusegun Sheyin, MD, Department of Medicine, Harlem Hospital Center, 506 Lenox Avenue, New York, NY 10037, United States of America, tel: 212 939 2296, fax: 212 939 2263, e-mail: [olusegun.sheyin@nychhc.org](mailto:olusegun.sheyin@nychhc.org)

Received: 05.09.2015

Accepted: 30.10.2015

prasugrel or ticagrelor, reduces the risk of stent thrombosis [2]. However, the optimal duration of DAPT following DES implantation at percutaneous coronary intervention remains unknown. The American Heart Association/American College of Cardiology recommend DAPT to be extended to at least 12 months after DES implantation if patients are not at high risk of bleeding [3]. Conversely, the European Society of Cardiology recommends from 6 to 12 months of DAPT for patients following elective percutaneous coronary intervention (PCI) and DES implantation, or 12 months in acute coronary syndromes [4]. These guidelines are largely based on observational studies which showed that early discontinuation of P2Y<sub>12</sub> receptor inhibitor therapy increased the risk of stent thrombosis [5–7]. Several randomized controlled trials (RCTs) comparing various durations of DAPT did not find any statistically significant differences in stent thrombosis rates [8–16]. However, these RCTs were not adequately powered to detect a statistically significant difference because of event rates being lower than expected and failure to recruit enough patients [11, 12, 16]. To address this limitation, a few meta-analyses have been conducted on the subject [17–22]. However, only the meta-analyses of RCTs by Pandit et al. [19], Liu et al. [18] and El-Hayek et al. [20] compared  $\leq 6$ -month DAPT with  $\geq 12$ -month DAPT. Finding no difference in efficacy outcomes between short- and long-term DAPT in these meta-analyses may have also been due to the low overall event rates. In addition, no sub-group analyses were performed in earlier meta-analyses. Hence, we conducted an updated meta-analysis of RCTs to determine the efficacy and safety of short-term ( $\leq 6$  months) DAPT as compared with long-term ( $\geq 12$  months) DAPT following DES implantation.

## Methods

We conducted a systematic review and meta-analysis, using methods that are in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommended by the Cochrane collaboration [23].

### Study research

MEDLINE, EMBASE, Scopus and CENTRAL databases were systematically searched from inception to January 2015 for all published RCTs in humans that compared outcome in patients receiving short-term ( $\leq 6$  months) DAPT with long-term ( $\geq 12$  months) DAPT following DES implantation.

Medical Subject Headings (MeSH) key terms ‘duration’, ‘dual antiplatelet therapy’, ‘DAPT’, ‘drug-eluting stent’ and ‘DES’ were used for the search. We subsequently searched and evaluated all reference lists of eligible articles obtained from the electronic search, and online resources such as Cardiosource and ClinicalTrials.gov to ensure identification of all published and unpublished studies on the subject.

### Study selection, data extraction and endpoints

Two investigators (O.S. and X.P.) independently identified and scrutinized studies for potential inclusion based on title or title and abstract. Full articles were then retrieved for further assessment, and disagreements were resolved by consensus and discussion with a third investigator (B.P.-L.).


The primary endpoint of this analysis was a composite of all-cause mortality, myocardial infarction (MI), target vessel revascularization (TVR), stroke, or major bleeding. The secondary outcome were the individual components of the primary outcome, cardiovascular death, stent thrombosis and any bleeding episode. Major bleeding was also defined according to the Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events (REPLACE-2) as intracranial, intraocular, or retroperitoneal bleed, overt blood loss with a  $> 3$  g/dL decrease in hemoglobin, any hemoglobin decrease  $> 4$  g/dL, or transfusion of  $\geq 2$  units of blood products; or according to the severe or life-threatening Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) criteria as intracranial bleeding or bleeding which resulted in substantial hemodynamic compromise requiring intervention [24–27].

### Selection criteria

We applied the following screening criteria to determine qualitative eligibility: original article; patients at least 18 years of age; duration of follow-up of at least 1 year; reported primary endpoint; and at least 100 patients included. Exclusion criteria applied included: on-going RCTs, RCTs comparing longer durations of DAPT, non-RCTs, editorial comments, reviews, and conference abstracts.

### Quality assessment

The methodological quality of each trial was evaluated for risk of bias using standard criteria in the following areas: method of randomization; allocation concealment; patient, investigator, and



**Figure 1.** Study flow diagram; DAPT — dual antiplatelet therapy; RCTs — randomized controlled trials.

outcome assessor blinding; selective outcome reporting; incomplete outcome ascertainment; and other potential sources of bias as recommended by the Cochrane collaboration [28].

### Statistical analysis

Data from each trial were entered on an intention-to-treat basis. Baseline characteristics were summarized and the differences between the two groups were compared using the Student's *t* tests for continuous variables and the  $\chi^2$  test for categorical variables. The included studies were compared with risk ratios (RRs) as the measure of effect. Heterogeneity was assessed using Cochran's *Q* statistic and  $I^2$  statistic ( $[Q - df]/Q \times 100$ ) and was considered present at  $p < 0.10$  and  $I^2 > 50\%$  [29]. Pooling was performed according to the fixed effect model with summary effect estimates (95% confidence intervals). To assess for publication bias risk, funnel plots were evaluated.

### Sensitivity analysis

Sensitivity analyses examining the robustness of the results were explored by comparing

fixed-effect results with both random effects and Yusuf-Peto models. In addition, each study was sequentially removed to see if it impacts the pooled effect estimate. Sub-group analyses were performed according to trial duration, age  $\geq 65$  years, and patients with acute coronary syndrome (ACS), diabetes, reduced left ventricular ejection fraction (LVEF), complex lesions, and multi-vessel disease.

Two-sided *p* values were calculated, with a *p* value less than 0.05 considered significant for all tests. Statistical analyses were performed with Comprehensive Meta-Analysis version 3 software.

### Results

Database search and other sources totally provided 4112 records. Of these records, 3,792 were excluded for various reasons (Fig. 1). Three hundred and twenty abstracts were assessed for eligibility from which 83 full articles were retrieved. However, only 7 RCTs fulfilled the inclusion and exclusion criteria mentioned above. The 7 RCTs recruited 15,378 patients across 229 sites worldwide (Table 1) [10–16].

Table 1. Characteristics of the included studies.

	EXCELLENT		ISAR-SAFE		ITALIC		OPTIMIZE		PRODIGY		RESET		SECURITY	
	Short (n = 722)	Prolonged (n = 721)	Short (n = 1997)	Prolonged (n = 2003)	Short (n = 912)	Prolonged (n = 910)	Short (n = 1563)	Prolonged (n = 1556)	Short (n = 737)	Prolonged (n = 741)	Short (n = 1059)	Prolonged (n = 1058)	Short (n = 682)	Prolonged (n = 717)
<b>Presentation:</b>														
SA/silent ischemia	353 (48.9%)	346 (48.0%)	1189 (59.5%)	1183 (59.1%)	560 (61.4%)	561 (61.6%)	1069 (68.4%)	1054 (67.7%)	194 (26.5%)	198 (26.7%)	471 (44.5%)	490 (46.3%)	341 (61.6%)	368 (61.6%)
ACS	369 (51.1%)	375 (52%)	794 (39.8%)	807 (40.3%)	211 (23.1%)	217 (23.8%)	494 (31.6%)	502 (32.3%)	542 (73.5%)	543 (73.3%)	588 (55.5%)	568 (53.7%)	213 (38.4%)	229 (38.4%)
<b>DES type:</b>														
Sirolimus	182 (25.2%)	182 (25.2%)	499 (25%)	483 (24.1%)	-	-	-	-	-	-	-	383 (28.5%)	-	-
Pacitaxel	-	-	44 (2.2%)	46 (2.3%)	-	-	-	-	245 (33.2%)	245 (33.1%)	-	-	-	-
Everolimus	540 (74.8%)	539 (74.8%)	948 (47.5%)	987 (49.3%)	912 (100%)	910 (100%)	-	-	247 (33.5%)	248 (33.5%)	-	404 (30.0%)	-	-
Zotarolimus	-	-	311 (15.6%)	294 (14.7%)	-	-	1563 (100%)	1556 (100%)	245 (33.2%)	248 (33.5%)	1341 (100%)	559 (41.5%)	470 (42.1%)	464 (40.3%)
Biolimus	-	-	166 (8.3%)	170 (8.5%)	-	-	-	-	-	-	-	-	363 (32.5%)	400 (34.8%)
<b>Duration of DAPT</b>	6 months	12 months	6 months	12 months	6 months	24 months	3 months	12 months	6 months	24 months	3 months	12 months	6 months	12 months
<b>Duration of follow-up</b>	12 months		15 months		36 months		12 months		24 months		12 months		12 months	
<b>Major exclusion criteria</b>	MI within 72 h Cardiogenic shock LVEF < 25% Prior stent in target vessel True bifurcation lesion requiring 2 stents strategy Left main stenosis > 50% Chronic total occlusion Serum creatinine ≥ 3.0 mg/dL Elective surgery planned within 12 months Life expectancy < 1 year		Clinical symptoms or signs of ischemia and/or angiographic lesions requiring revascularization Active bleeding, bleeding diathesis or history of intracranial bleeding STEMI and NSTEMI in the past 6 months after DES Previous stent thrombosis Prior stent in left main artery Oral anticoagulation therapy Planned major surgery within 6 months with need to discontinue APT		Prior DES implantation within 1 year Platelet count < 100,000/μL or bleeding diathesis Oral anticoagulation therapy or abciximab Contraindication to APT Major surgery within preceding 6 weeks GI/GU bleeding Severe liver failure Planned surgery within 1 year after enrolment		Primary rescue PCI for STEMI BMS in non-target vessel in the last 6 months Previous DES Saphenous vein graft lesion Scheduled elective surgery within 12 months after PCI Known hypersensitivity to APT In-stent restenosis of a DES		Concomitant or foreseeable need for oral anticoagulation Known allergy to APT Planned surgery within 24 months of PCI Major surgery within 15 days Active bleeding or previous stroke within 6 months Life expectancy < 24 months		STEMI within 48 h Cardiogenic shock LVEF < 40% Cerebral/peripheral atherosclerotic disease Thrombo-embolic disease Prior stent thrombosis Left main disease Chronic total occlusion Re-stenotic lesion		Saphenous vein graft In-stent restenosis Unprotected left main artery STEMI within 48 h NSTEMI in prior 6 months LVEF ≤ 30% Known hypersensitivity to APT, heparin, or contrast media History of thrombo-cytopenia with APT CKD (creatinine > 2 mg/dL) Active bleeding Life expectancy < 24 months	



**Table 1. cont.** Characteristics of the included studies.

	EXCELLENT		ISAR-SAFE		ITALIC		OPTIMIZE		PRODIGY		RESET		SECURITY	
	Short (n = 722)	Prolonged (n = 721)	Short (n = 1997)	Prolonged (n = 2003)	Short (n = 912)	Prolonged (n = 910)	Short (n = 1563)	Prolonged (n = 1556)	Short (n = 737)	Prolonged (n = 741)	Short (n = 1059)	Prolonged (n = 1058)	Short (n = 682)	Prolonged (n = 717)
<b>Primary end point</b>	Target vessel failure (composite cardiac death, MI or TVR during the 12-month period after randomization)	Composite of death, MI, stent thrombosis, stroke or TIMI major bleeding 15 months after DES	Composite of death, MI, stent thrombosis, stroke or TIMI major bleeding 12 months of stenting	Composite of death, MI, repeat emergency TVR, stroke or TIMI major bleeding within 12 months of stenting	Composite of death, MI, repeat emergency TVR, stroke or TIMI major bleeding within 12 months of stenting	Composite of death, MI, repeat emergency TVR, stroke or TIMI major bleeding within 12 months of stenting	Net adverse clinical and cerebral events (NACCE): composite of death from any cause, MI, stroke or major bleeding	Net adverse clinical and cerebral events (NACCE): composite of death from any cause, MI, stroke or major bleeding	Death from any cause, non-fatal MI or cerebrovascular accident	Death from any cause, non-fatal MI or cerebrovascular accident	Composite of death from all causes, MI or stent thrombosis	Composite of death from all causes, MI or stent thrombosis	Composite of cardiac death, MI, stroke, definite or probable stent thrombosis and BARC criteria type 3 or 5	Composite of cardiac death, MI, stroke, definite or probable stent thrombosis and BARC criteria type 3 or 5
<b>Secondary end point</b>	Individual components of the primary end point Death from any cause Death or MI Stent thrombosis Major bleeding (TIMI criteria) MACCE: death, MI, stroke or any revascularization Safety end point: death, MI, stroke, stent thrombosis or TIMI major bleeding	Individual components of the primary end point Death from any cause Death or MI Stent thrombosis Major bleeding (TIMI criteria) MACCE: death, MI, stroke or any revascularization Safety end point: death, MI, stroke, stent thrombosis or TIMI major bleeding	Individual components of the primary end point Death from any cause Death or MI Stent thrombosis Major bleeding (TIMI criteria) MACCE: death, MI, stroke or any revascularization Safety end point: death, MI, stroke, stent thrombosis or TIMI major bleeding	Individual components of the primary end point Death from any cause Death or MI Stent thrombosis Major bleeding (TIMI criteria) MACCE: death, MI, stroke or any revascularization Safety end point: death, MI, stroke, stent thrombosis or TIMI major bleeding	Individual components of the primary end point Death from any cause Death or MI Stent thrombosis Major bleeding (TIMI criteria) MACCE: death, MI, stroke or any revascularization Safety end point: death, MI, stroke, stent thrombosis or TIMI major bleeding	Individual components of the primary end point Death from any cause Death or MI Stent thrombosis Major bleeding (TIMI criteria) MACCE: death, MI, stroke or any revascularization Safety end point: death, MI, stroke, stent thrombosis or TIMI major bleeding	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident	Individual components of the primary end point Death from any cause, non-fatal MI or cerebrovascular accident
<b>P2Y12 inhibitor</b>	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel, prasugrel, ticagrelor	Clopidogrel, prasugrel, ticagrelor	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel	Clopidogrel
<b>Trial setting</b>	19 sites in Korea	40 sites in Europe, China, Japan and USA	40 sites in Europe, China, Japan and USA	70 sites in Europe and the Middle East	70 sites in Europe and the Middle East	70 sites in Europe and the Middle East	33 sites in Brazil	33 sites in Brazil	3 sites in Italy	3 sites in Italy	26 sites in Korea	26 sites in Korea	38 sites in Italy, Spain and the Netherlands	38 sites in Italy, Spain and the Netherlands

ACS — acute coronary syndrome; APT — antiplatelet therapy; BARC — Bleeding Academic Research Consortium; BMS — bare metal stent; CABG — coronary artery bypass grafting; CKD — chronic kidney disease; DAPT — dual antiplatelet therapy; DES — drug eluting stent; GI — gastro-intestinal; GU — genitourinary; GUSTO — Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries; LVEF — left ventricular ejection fraction; MACCE — major adverse cardiac and cerebrovascular events; MACE — major adverse cardiac events; MI — myocardial infarction; NACCE — net adverse clinical and cerebral events; NSTEMI — non-ST elevation myocardial infarction; PCI — percutaneous coronary intervention; REPLACE-2 — Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events; SA — stable angina; STEMI — ST elevation myocardial infarction; TIMI — Thrombolysis in Myocardial Infarction; TVR — target vessel revascularization



**Table 2.** Baseline patient clinical and angiographic characteristics.

Variables	≤ 6-month DAPT (n = 7672)	≥ 6-month DAPT (n = 7706)	P
Age [years]	64.1 ± 10.2	64.3 ± 10.4	0.23
Male gender	5595 (72.9%)	5591 (72.6%)	0.98
Hypertension	5942 (77.5%)	6026 (78.2%)	0.94
Diabetes mellitus	2359 (30.7%)	2366 (30.7%)	1.00
Dyslipidemia	5313 (69.3%)	5363 (69.6%)	0.97
Current smoker	1834 (23.9%)	1815 (23.6%)	0.96
Previous MI	1613 (21.0%)	1564 (20.3%)	0.89
Previous PCI <sup>a</sup>	783 (15.9%)	712 (14.3%)	0.77
Previous CABG	570 (7.4%)	566 (7.3%)	0.97
Congestive heart failure <sup>b</sup>	895 (14.3%)	904 (14.5%)	0.97
Clinical presentation:			
Stable angina/silent ischemia	4177 (54.4%)	4200 (54.5%)	0.99
Unstable angina/NSTEMI	2880 (37.5%)	2891 (37.5%)	1.00
STEMI	416 (5.4%)	434 (5.6%)	0.94
LVEF <sup>c</sup>	59.0 ± 14.8	58.9 ± 14.2	0.67
Discharge medications <sup>d</sup> :			
ACE-inhibitor	555 (31.2%)	592 (33.3%)	0.88
ARB	567 (31.8%)	532 (29.9%)	0.89
Beta-blocker	1139 (64.0%)	1175 (66.0%)	0.92
Statin	1527 (85.7%)	1496 (84.1%)	0.94
Angiographic findings:			
Single vessel disease	3948 (51.5%)	3991 (51.8%)	0.97
Multi-vessel disease	3724 (48.5%)	3715 (48.2%)	0.97
LAD lesion	4434 (57.8%)	4446 (57.7%)	0.99
Left circumflex artery lesion <sup>e</sup>	2115 (30.4%)	2069 (29.6%)	0.90
RCA lesion <sup>e</sup>	2515 (36.2%)	2557 (36.6%)	0.96
Left main lesion <sup>e</sup>	48 (0.69%)	42 (0.60%)	0.93
CABG <sup>e</sup>	94 (1.4%)	83 (1.2%)	0.88
Complex lesions (ACC/AHA B2, C)	5289 (61.1%)	5187 (59.5%)	0.85

<sup>a</sup>No data available from ISAR-SAFE and PRODIGY; <sup>b</sup>No data available from PRODIGY and SECURITY; <sup>c</sup>No data available from ISAR-SAFE, ITALIC and OPTIMIZE; <sup>d</sup>Data available from EXCELLENT and RESET; <sup>e</sup>No data available from EXCELLENT; DAPT — dual antiplatelet therapy; MI — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery bypass grafting; STEMI — ST elevation MI; NSTEMI — non-ST elevation MI; LVEF — left ventricular ejection fraction; ACE — angiotensin converting enzyme; ARB — angiotensin receptor blocker; LAD — left anterior descending coronary artery; RCA — right coronary artery; ACC — American College of Cardiology; AHA — American Heart Association


In order to receive short-term DAPT and long-term DAPT, 7672 and 7706 patients were randomized, respectively. The two groups studied were similar with respect to baseline clinical and angiographic characteristics (Table 2). Women were under-represented when compared with men. All the trials except PRODIGY exclusively utilized DES for PCI. In order to maintain consistency in our analysis, we included data from the DES subgroup in the PRODIGY trial that was subsequently published [14]. Follow-up duration was 12 months in 4 trials [10, 13, 15, 16], and

15 months, 24 months and 36 months in the remaining 3 trials [11, 12, 14]. The composite primary end-point was similar in all 7 studies, except for the non-inclusion of stroke in 2 studies [10, 15] and bleeding in 1 study [14].

### Endpoints

The endpoints are shown in Figures 2 and 3.

**Primary endpoint.** The primary outcome occurred in 309 (4.0%) patients who received short-term DAPT and in 305 (4.0%) patients who received long-term DAPT. There were no statis-



**Figure 2.** Forest plot reporting the risk ratios with 95% confidence intervals (CI) (designated lower limit and upper limit) of the primary outcome (A) and major bleeding (B) in patients from 7 randomized controlled trials treated with short-term ( $\leq 6$  months) dual antiplatelet therapy (DAPT) compared with patients treated with long-term ( $\geq 12$  months) DAPT.

tically significant differences between the short-term and long-term DAPT groups with respect to the occurrence of the primary outcome (pooled risk ratio [pRR] 1.02; 0.87–1.19;  $I^2 = 0\%$ ) (Fig. 2).

**Secondary endpoints.** There was no statistically significant difference in risk of all-cause mortality (pRR 0.90; 0.71–1.13;  $I^2 = 0\%$ ), cardiovascular death (pRR 0.92; 0.67–1.28;  $I^2 = 0\%$ ), MI (pRR 1.14; 0.89–1.46;  $I^2 = 0\%$ ), stent thrombosis (pRR 1.264; 0.79–2.03;  $I^2 = 0\%$ ), TVR (pRR 1.17; 0.91–1.51;  $I^2 = 0\%$ ), and cerebrovascular accidents (pRR 0.88; 0.69–1.61;  $I^2 = 0\%$ ), between short and long duration of DAPT. However, major bleeding occurred in 28 (0.4%) patients in the short-term DAPT group and in 51 (0.7%) patients who received long-term DAPT. As shown in Figures 2 and 3, there was a significantly lower risk of major bleeding with short-term DAPT when compared with the long-term DAPT group (pRR 0.57; 0.36–0.90;  $I^2 = 0\%$ ;  $p = 0.02$ ).

### Sensitivity and sub-group analyses

Similar results were obtained when analysis was performed using the fixed-effects, random effects and Yusuf-Peto models. Sequential removal of each study from the analysis did not impact


the pooled effect estimate. As shown in Figure 3, there was no statistically significant difference in risk of the primary endpoint among patients presenting with ACS (pRR 1.06; 0.79–1.44;  $I^2 = 0\%$ ), patients with diabetes (pRR 1.03; 0.75–1.42;  $I^2 = 0\%$ ), reduced LVEF (pRR 0.81; 0.44–1.49;  $I^2 = 0\%$ ), complex lesions (pRR 1.00; 0.75–1.33;  $I^2 = 0\%$ ), multi-vessel disease (pRR 1.24; 0.88–1.73;  $I^2 = 0\%$ ), and patients at least 65 years of age (pRR 0.83; 0.75–1.33;  $I^2 = 0\%$ ) who received short-term DAPT as compared with long-term DAPT.

There was no statistically significant difference in risk of the primary endpoint between patients treated with 3–6 months of DAPT vs. 12-month DAPT (pRR 1.04; 0.87–1.25;  $I^2 = 0\%$ ), 6 months vs. 12 months of DAPT (pRR 1.09; 0.81–1.46;  $I^2 = 0\%$ ), 3 months vs. 12 months of DAPT (pRR 1.01; 0.79–1.30;  $I^2 = 0\%$ ), or 6 months vs. 24 months of DAPT (pRR 0.95; 0.69–1.31;  $I^2 = 0\%$ ).

## Discussion

### Findings

In our meta-analysis of 15,378 patients who received DES following PCI, we did not find any difference in risk of the primary outcome, all-



**Figure 3.** Pooled analysis of studies comparing short-term ( $\leq 6$  months) dual antiplatelet therapy (DAPT) with long-term ( $\geq 12$  months); **A.** Forest plot reporting summary risk ratios with 95% confidence intervals (CI) (designated lower limit and upper limit) for the comparison of  $\leq 6$  months DAPT vs.  $\geq 12$  months DAPT with respect to the primary outcome, all cause death, cardiovascular death, myocardial infarction, definite or probable stent thrombosis, target vessel revascularization (TVR), stroke and major bleeding; **B.** Forest plot reporting summary risk ratios with 95% CI of the comparison in various sub-groups; m — months; LVEF — left ventricular ejection fraction.

-cause mortality, cardiovascular death, MI, TVR, stent thrombosis, and cerebrovascular accidents between the short-term and long-term DAPT groups. However, patients treated with short-term DAPT were at a significantly lower risk of major bleeding. We did not find any difference in the risk of the primary endpoint based on DAPT duration and on sub-group analyses, according to age and the presence of diabetes, ACS, reduced LVEF, complex lesions, or multi-vessel disease.

**Comparison with other studies**

The findings of this study are similar to the 3 previously published meta-analyses comparing  $\leq 6$ -month DAPT with  $\geq 12$ -month DAPT [18–20]. In addition to the 4 studies included in the El-Hayek et al. [20] and Pandit et al. [19] meta-analyses, our study included 3 recently published studies: ISAR-SAFE, ITALIC and SECURITY [11, 12, 16]. The findings from our study are more robust due to the sample size, nearly twice as large as those in the earlier meta-analysis and due to the performance of analyses in high-risk patient sub-groups. Since

our study is investigating the efficacy and safety of even shorter duration of DAPT when compared to the standard recommended therapy of at least 12 months, RCTs with short-term DAPT duration more than 6 months were excluded.

Concerns regarding the safety of short-term DAPT were raised in the meta-analysis of 8157 patients by Hayek et al. [20] because of the finding of an almost 2-fold (1.75), though non-significant risk of stent thrombosis among patients who discontinued P2Y12 therapy after 6 months. In comparison, the risk of stent thrombosis in our study, with almost twice as many patients was 1.26. Nevertheless, the recently published DAPT study with 9961 patients comparing 12-month DAPT with 30-month DAPT found a statistically significant decrease in the rate of stent thrombosis [30], suggesting that the trend of increased risk of stent thrombosis found in our study and the earlier meta-analyses may become significant if patients are followed longer. Even though the DAPT study also demonstrated a significant decrease in MI and major cardiovascular and cerebrovascular events



(MACCE) with 30 months of DAPT, there was a paradoxical increased risk of all-cause mortality with prolonged DAPT when the analysis was conducted at 33 months (hazard ratio [HR] 1.36;  $p = 0.04$ ). Furthermore, the increase in stent thrombosis, MI and MACCE with 12-month DAPT did not translate to an increased risk of death, as there was no difference in death from cardiac or vascular causes (HR 1.00; 0.66–1.52 and 0.98; 0.28–3.39, respectively). Hence prolonging DAPT duration to 30 months had no effect on cardiovascular mortality, but led to an almost 2-fold increase in non-cardiovascular mortality (HR 1.86;  $p = 0.01$ ).

### Clinical implications

Our study confirms the finding that  $\leq 6$  months of DAPT is equally effective as  $\geq 12$  months of DAPT reported by previously published RCTs with much smaller sample sizes and potential for type II error. In addition, we found that long-term DAPT is associated with increased risk of major bleeding events. Hence, long-term DAPT has the potential of leading to increased morbidity, in addition to higher cost of treatment and pill burden when compared with short-term DAPT.

### Strengths and limitations of the study

This is the largest meta-analysis to date on RCTs comparing outcome in patients receiving  $\leq 6$ -month DAPT with  $\geq 12$ -month DAPT following DES implantation. All the studies included were of high quality and visual inspection of the funnel plot did not reveal any evidence of publication bias. In addition, our meta-analysis is the first to demonstrate no difference in outcome between short-term and long-term DAPT even among the high-risk patient sub-groups, including patients presenting with ACS and patients with diabetes, severely depressed LVEF, complex lesions, and multi-vessel disease.

As expected in any meta-analysis, our study utilized data that were reported in each of the included RCTs. With the exception of the ISAR-SAFE trial, all the included RCTs were not double blind but open-label by design, which introduces the possibility of ascertainment bias in the results. There is also a possibility that selection bias may have been present, since none of the studies reported whether allocation concealment was performed. However, there were no differences between the two groups in the baseline characteristics of the included subjects. Despite pooling data from 15,378 patients, the total number of stent thrombosis events remained low ( $< 0.5\%$ ). Hence, our analysis

has the potential for a type II error. Analysis according to the type of implanted DES was not possible due to the fact that this information was available only in 2 of the included studies. Finally, with the exception of 1 trial, our study included only RCTs of patients who were treated with the P2Y12 inhibitor clopidogrel. The trial in which patients were treated with ticagrelor, prasugrel or clopidogrel did not report outcome based on the P2Y12 treatment received. Thus, it is uncertain whether the use of newer more potent P2Y12 inhibitors, including ticagrelor and prasugrel, would alter the safety and efficacy of prolonged DAPT.

### Conclusions

This meta-analysis did not find any difference in efficacy outcomes between short-term and long-term DAPT following DES. Short-term DAPT was equally effective as long-term DAPT in preventing the primary outcome even in high-risk patients. However, longer duration of DAPT was found to be associated with increased risk of major bleeding in our study, in addition to increased non-cardiovascular and all-cause mortality demonstrated in the DAPT study. Larger, adequately powered RCTs for low event rates are needed to confirm these findings.

**Conflict of interest:** None declared

### References

1. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. *Circulation* 2006; 114: 798e806.
2. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. *JAMA*, 2005; 293: 2126e2130.
3. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol*, 2011; 58: e44–e122.
4. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. *Eur Heart J*, 2010; 31: 2501–2555.
5. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. *J Am Med Assoc*, 2005; 293: 2126–2130.
6. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *J Am Med Assoc*, 2007; 297: 159–168.
7. Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. *Am J Cardiol*, 2006; 98: 352–356.

8. Park SJ, Park DW, Kim YK et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. *New Engl J Med*, 2010; 362: 1374–1382.
9. Valgimigli M, Campo G, Monti M et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. *Circulation*, 2012; 125: 2015–2026.
10. Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug eluting stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. *Circulation*, 2012; 125: 505–513.
11. Schulz-Schupke S, Byrne RA, Ten Berg JM et al. ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J*, 2015; 36: 1252–1263. doi: 10.1093/eurheartj/ehu523.
12. Gilard M, Barragan P, Noryani AA et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. *J Am Coll Cardiol*, 2014; 65: 777–786. doi: 10.1016/j.jacc.2014.11.008.
13. Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. *J Am Med Assoc*, 2013; 310: 2510–2522.
14. Valgimigli M, Borghesi M, Tebaldi M et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). *Eur Heart J*, 2013; 34: 909–919.
15. Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). *J Am Coll Cardiol*, 2012; 60: 1340–1348.
16. Colombo A, Chieffo A, Frasheri A et al. Second generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy. The SECURITY randomized clinical trial. *J Am Coll Cardiol*, 2014; 64: 2086–2097.
17. Kwok CS, Bulluck H, Ryding AD et al. Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: a meta-analysis. *Scientific World J*, 2014; 2014: 794078. doi: 10.1155/2014/794078. eCollection 2014.
18. Liu M, Chen J, Huang D et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis of 3 randomized controlled trials. *J Cardiovasc Pharmacol*, 2014; 64: 41–46.
19. Pandit A, Giri S, Hakim FA et al. Shorter ( $\leq 6$  months) versus longer ( $\geq 12$  months) duration dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized clinical trials. *Catheterization Cardiovasc Intervent*, 2015; 85: 34–40.
20. El-Hayek G, Messerli F, Bangalore S et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. *Am J Cardiol*, 2014; 114: 236–242.
21. Cassese S, Byrne RA, Tada T et al. Clinical impact of extended dual antiplatelet therapy after percutaneous interventions in the drug-eluting stent era: A meta-analysis of randomized trials. *Eur Heart J*, 2012; 33: 3078–3087.
22. Elmariah S, Mauri L, Doros G et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. *Lancet*, 2015; 385: 792–798. doi.org/10.1016/S0140-6736(14)62052-3.
23. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. *BMJ*, 2009; 339: b2700.
24. Bovill EG, Terrin ML, Stump DC et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. *Ann Intern Med*, 1991; 115: 256–265.
25. Mehran R, Rao SV, Bhatt DL et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium. *Circulation*, 2011; 123: 2736–2747.
26. Feit F, Voeltz MD, Attubato MJ et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. *Am J Cardiol*, 2007; 100: 1364–1369.
27. Topol EJ, Armstrong P, Van de Werf F, et al.; Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. *J Am Coll Cardiol*, 1992; 19: 1123–1128.
28. Higgins JP, Altman DG, Gøtzsche PC et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. *BMJ*, 2011; 343: 5928.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*, 2002; 21: 1539–1558.
30. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *New Engl J Med*, 2014; 371: 2155–2166.